The ROSE (Risk Stratification of Syncope in the Emergency Department) Study  by Reed, Matthew J. et al.
T
w
o
(
o
l
F
a
E
U
p
B
R
t
a
s
d
a
Journal of the American College of Cardiology Vol. 55, No. 8, 2010
© 2010 by the American College of Cardiology Foundation ISSN 0735-1097/10/$36.00
PQUARTERLY FOCUS ISSUE: HEART RHYTHM DISORDERS Clinical Research
Syncope
The ROSE (Risk Stratification of
Syncope in the Emergency Department) Study
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Andrew J. Coull, BSC, MB, CHB, MD,‡ Robin J. Prescott, BSc, MSc, PHD,§
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Objectives The aim of this study was to develop and validate a clinical decision rule (CDR) to predict 1-month serious out-
come and all-cause death in patients presenting with syncope to the emergency department.
Background Syncope is a common, potentially serious condition accounting for many hospital admissions.
Methods This was a single center, prospective, observational study of adults presenting to the emergency department
with syncope. A CDR was devised from 550 patients in a derivation cohort and tested in a validation cohort of a
further 550 patients.
Results One-month serious outcome or all-cause death occurred in 40 (7.3%) patients in the derivation cohort. Indepen-
dent predictors were brain natriuretic peptide concentration 300 pg/ml (odds ratio [OR]: 7.3), positive fecal
occult blood (OR: 13.2), hemoglobin 90 g/l (OR: 6.7), oxygen saturation 94% (OR: 3.0), and Q-wave on the
presenting electrocardiogram (OR: 2.8). One-month serious outcome or all-cause death occurred in 39 (7.1%)
patients in the validation cohort. The ROSE (Risk stratification Of Syncope in the Emergency department) rule
had a sensitivity and specificity of 87.2% and 65.5%, respectively, and a negative predictive value of 98.5%. An
elevated B-type natriuretic peptide (BNP) concentration alone was a major predictor of serious cardiovascular
outcomes (8 of 22 events, 36%) and all-cause deaths (8 of 9 deaths, 89%).
Conclusions The ROSE rule has excellent sensitivity and negative predictive value in the identification of high-risk patients
with syncope. As a component, BNP seems to be a major predictor of serious cardiovascular outcomes and all-
cause death. The ROSE rule and BNP measurement might be valuable risk stratification tools in patients with
emergency presentations of syncope and should now be subjected to external validation. (J Am Coll Cardiol
2010;55:713–21) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.09.049v
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hhere have been several risk stratification studies in patients
ith syncope (1–8), but many are limited by small numbers
f patients in the derivation cohort (n  175 to 270)
1,3,4,8), whereas others have not been validated (2,7), and
nly 2 have looked at short-term outcome (5–7). In the
arge San Francisco Syncope Rule (derivation n  684;
rom the *Department of Emergency Medicine, †Centre for Cardiovascular Sciences,
nd the ‡Department of Medicine of the Elderly, Royal Infirmary of Edinburgh,
dinburgh, United Kingdom; and the §Centre for Population Health Sciences,
niversity of Edinburgh, Medical School, Edinburgh, United Kingdom. The
oint-of-care BNP test strips and Triage point-of-care machine were supplied by
iosite for the pilot study. Biosite provided no funding for the main ROSE study. Dr.
eed received a travel bursary from Biosite to present the results of the pilot study to
he 4th Mediterranean Congress of Emergency Medicine and received funding from
Chief Scientist Office research fellowship (CSO/CAF/06/01). The sponsor of the
tudy had no role in study design, data collection, data management, data analysis,
ata interpretation, or writing of the report.s
Manuscript received June 8, 2009; revised manuscript received September 11, 2009,
ccepted September 22, 2009.alidation n  791) study, short-term adverse outcomes
elevant to emergency practice were examined (5,6), but
ttempts to validate it externally have failed (9–12). More-
ver, the potential role of biochemical markers in risk
tratification has not been assessed. B-type natriuretic pep-
ide (BNP) is an excellent marker of prognosis in patients
ith heart failure or cardiac disease (13). Given that
See page 722
rognosis in syncope is related to the presence of underlying
eart disease (14) and that all existing syncope clinical
ecision rules (CDRs) include either a history of congestive
eart failure (1,4–6) or underlying cardiac disease (2,3),
NP represents a promising and important biomarker that
as been underinvestigated in the context of syncope.
Definitions vary, but syncope can be defined as a “tran-ient, self-limited loss of consciousness, usually leading to
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cope is relatively rapid, and the
subsequent recovery is spontane-
ous, complete, and relatively
prompt. The underlying mecha-
nism is a transient global cerebral
hypoperfusion (15,16). Termi-
nology has recently been clarified
(17), and “transient loss of con-
sciousness” is now used to en-
compass both syncope and epi-
leptic seizures. Often the cause
for a specific event is unclear, and
in these patients, transient loss of
consciousness should be used.
The aims of the present study
ere to develop and to validate a CDR with history,
xamination, electrocardiogram (ECG), and biochemical
arkers to predict 1-month serious outcome and all-cause
eath in patients presenting with syncope to the emergency
epartment (ED).
ethods
tudy design and setting. This was a single-center, pro-
pective, observational derivation and validation cohort
tudy. The study was conducted in the Emergency Depart-
ent of the Royal Infirmary of Edinburgh: a United
ingdom tertiary center with 100,000 adult attendances per
nnum. The study was granted ethical approval by the
ulti-Centre Research Ethics Committees for Scotland A
thics committee (06/MRE00/107) and the Lothian Re-
ional Ethical Committee (06/S11ADMIN/151). Written
onsent or relative assent was obtained from all patients.
tudy population. Patients 16 years of age or older pre-
enting with acute syncope were enrolled. Exclusion criteria
ere no consent or relative assent, persisting neurological
eficit suggestive of stroke, previous recruitment into the
tudy, collapse related to alcohol consumption (raised al-
ometer reading and no other cause for syncope), hypogly-
emia, trauma, or seizure activity with a 15-min witness-
eported postictal phase (18).
tandardized patient assessment. Potentially eligible pa-
ients were identified in the ED triage area and assessed for
tudy inclusion by the attending clinician (an emergency
hysician or nurse practitioner). A decision to enroll a
atient was not later overturned. Data were collected with a
tructured data collection form with 32 predetermined
istorical variables (9 focused on clinical features, 10 on past
edical history, and 13 medication-related) and 14 exami-
ations, 24 ECGs, and 23 biochemical or hematological
ariables. These included all characteristics previously asso-
iated with serious outcome or used in existing CDRs and
uidelines. ED tests not part of the study protocol were
rdered at the discretion of the treating doctor, and patients
Abbreviations
and Acronyms
BNP  B-type natriuretic
peptide
CDR  clinical decision
rule
CI  confidence interval
ECG  electrocardiogram
ED  emergency
department
MI  myocardial infarction
OR  odds ratio
ROC  receiver-operator
characteristicere admitted, referred for outpatient investigation, or discharged according to current ED protocols. Point-of-
are BNP testing was performed with a 2.7-ml ethylenedia-
inetetraacetic acid sample with a Biosite Triage point-of-
are machine (Biosite Inc., San Diego, California).
utcome measures and assessment. The primary end
oint was the combination of serious outcome and all-cause
eath at 1 month after ED presentation. Serious outcome
ncompassed the following: 1) acute myocardial infarction
MI) according to the universal definition (19); 2) life-
hreatening arrhythmia (ventricular fibrillation, sustained
entricular tachycardia [120 beats/min], ventricular pause
3 s], ventricular standstill, or asystole); 3) decision to
mplant a pacemaker or cardiac defibrillator within 1 month of
ndex collapse; 4) pulmonary embolus (confirmed on lung
erfusion scan or CT pulmonary angiography); 5) cerebrovas-
ular accident, intracranial hemorrhage, or subarachnoid hem-
rrhage (demonstrated by brain imaging or lumbar puncture);
) hemorrhage requiring a blood transfusion of 2 U; or
) acute surgical procedure or endoscopic intervention. Sec-
ndary end points were cardiovascular serious outcome (acute
I, arrhythmia, pacemaker/defibrillator implantation, or car-
iac procedure) and syncope-related death (death due to cause
f presenting syncopal episode).
Patients were followed up 1 month after presentation
hrough the hospital Electronic Patient Record system, hospi-
al pacemaker records, radiological reports, and direct contact
ith the patient or general practitioner. A cardiologist (Jeremy
angrish) and emergency physician (M.J.R.) independently
eviewed all ECGs and agreed to findings by consensus. Two
nvestigators (M.J.R. and A.J.C.) independently reviewed all
erivation clinical data and assigned end points with any
isagreements resolved by consensus from 3 other investigators
D.E.N., K.G.J., and A.J.G.). All derivation group end points
ere assigned before development of the ROSE (Risk strati-
cation Of Syncope in the Emergency department) CDR.
ata analysis. Nonrecruited but potentially eligible pa-
ients were identified by a daily search of all Emergency
epartment Electronic Patient Records with Business Ob-
ects version 6.5 (Business Objects Enterprise, San Jose,
alifornia) looking for the keywords “syncope,” “collapse,”
faint,” “loss of consciousness,” or “loc.” All identified
lectronic Patient Records were reviewed (M.J.R.) and
lassified as eligible or ineligible. Five percent were inde-
endently audited at random by a second investigator
K.G.J.).
From pilot data, we estimated approximately 1,200 eli-
ible patients present to our ED each year and anticipated
ecruiting between 800 and 1,000 per annum. With an
stimated 1-month event rate of 10.0% (20,21) and a
ample size of 500 patients, the study has an 80% power of
howing an effect (p  0.05, 2-tailed), if the odds ratio
OR) for an SD change in the predictor value is 1.7. This
alculation allowed for a correlation of this variable with the
ther covariates such that R2  0.3. If a binary risk factor
as a prevalence of 20%, there will be an 80% power to
etect (p 0.05, 2-tailed) an increase in the event rate if the
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February 23, 2010:713–21 The ROSE StudyR is 2.5 (nQuery Advisor, Statistical Solutions, Boston,
assachusetts). If a risk factor has a prevalence of only 10%,
here is a corresponding 80% power to detect an OR of 3.2.
ecause of predicted loss to follow-up and missing data, we
imed to recruit a further 10% (i.e., a total of 550 patients)
o each cohort.
evelopment of the ROSE CDR. An expert panel con-
isting of 6 representatives from emergency, cardiovascular,
eneral, and geriatric medicine, and medical statistics met in
anuary 2007 to review the selected predictor variables and
efinitions of all end point measures and later to develop the
OSE CDR by consensus. Initially a principal component
nalysis was performed to reduce the number of variables for
onsideration, but this approach was unhelpful. Mean values
nd mean differences were calculated for continuous vari-
bles for serious and nonserious outcome groups. Continu-
us and categorical data were assessed by t test and chi-
quare test, respectively, to determine which variables
howed statistical significance (at p  0.10, 2-tailed).
Missing” was considered a category for categorical vari-
bles, whereas for continuous variables mean imputation
as used in conjunction with a binary dummy variable to
ndicate whether the numerical variable had been imputed.
ross tabulation was then performed to look for suitable
utoff points. Multiple logistic regression analysis was then
erformed to determine independent predictors of serious
utcome, and a weighted integer risk score based on the
oefficient derived from the logistic regression analysis was
ssigned. The combination of characteristics chosen, along
ith their risk score, was used to derive a total risk score that
as applied to the derivation cohort. On review by the
xpert panel, it was decided that this approach was not
ensitive enough or clinically sensible. A patient with only 1
ositive predictor might not score enough to be admitted,
espite a good predictor of serious outcome or death being
resent. A decision tree approach was therefore applied,
tarting with variables identified from the logistic regres-
ion. Variables that predicted adverse outcome were pro-
ressively identified to optimize the sensitivity of the rule.
his approach maintained sensitivity and was therefore
ccepted as the ROSE CDR.
alidation of the ROSE CDR. An independent clinician
David Caesar) blinded to the ROSE CDR, assigned all
alidation cohort end points. Patients lost to follow-up were
xcluded before statistical analysis. The sensitivity, specific-
ty, positive and negative predictive values, and positive and
egative likelihood ratios were calculated for the ROSE
DR in the validation cohort.
esults
erivation cohort. Between March 1, 2007, and October
7, 2007, there were 890 (1.3%) potentially eligible patients
rom 70,836 presentations to the ED. Patients (n  575;
4.6%) were screened, 13 refused to consent, and 12 were
nable to consent and had no relative or caregiver who could crovide assent. The derivation cohort therefore consisted of
50 patients (Fig. 1). Nineteen patients were lost to follow-
p, and 2 patients had been previously enrolled into the
erivation cohort and were excluded. This left 529 patients
or analysis (Table 1), of whom 40 patients had a primary
utcome (Table 2).
evelopment of the ROSE CDR. Variables found by
ultiple logistic regression analysis to be independent
redictors of serious outcome were BNP concentration
300 pg/ml (Wald chi-square: 15.9, OR: 7.3), a rectal
xamination showing fecal occult blood (chi-square: 13.6,
R: 13.2), hemoglobin90 g/l (chi-square: 11.0, OR: 6.7),
-waves (25% of R-wave, width 0.04 s, depth 2 mm,
nd not in lead III; chi-square: 5.8, OR: 2.8) or left bundle
ranch block (chi-square: 5.3, OR: 4.8) on the presenting
CG, male sex (chi-square: 5.2, OR: 2.6), oxygen satura-
ion 94% on room air (chi-square: 5.1, OR: 3.0), albumin
37 g/l (chi-square: 2.9, OR: 3.2), and white cell count
14  109 cells/l (chi-square: 2.5, OR: 2.4).
With recursive partitioning to create a decision tree and
o prioritize sensitivity, BNP concentration 300 pg/ml
ccounted for 13 of 40 patients with an event. This cutoff
aximized its specificity without losing any sensitivity for
etecting serious outcome or all-cause death. Rectal exam-
nation showing fecal occult blood accounted for a further 8
atients, hemoglobin concentration 90 g/l, and oxygen
aturation 94% on room air accounted for 4 more
atients each; and Q-wave (not in lead III) on the ECG
dentified 3 patients. Analysis of the remaining 8 patients
howed that “chest pain associated with syncope” and
bradycardia 50 beats/min” accounted for a further 5
atients, leaving just 3 unidentified patients. Albumin
nd white cell count were not included, because they are
ot immediately available to the emergency clinician;
ale sex was removed, because it was not useful within a
undle approach.
The 3 unidentified cases were an endoscopy procedure
howing severe gastro-esophageal reflux, a computed to-
ography guided biopsy procedure, and a pacemaker for
ersistent neurocardiogenic syncope. It was felt by the study
nvestigators that these outcomes were not, in reality, life
hreatening although defined as “serious” by the study
rotocol. Figure 2 shows the finalized ROSE rule. A patient
hould be considered high-risk for serious outcome and
dmission considered if 1 or more of the 7 characteristics is
resent. The sensitivity, specificity, positive and negative
redictive values, and positive and negative likelihood ratios
f the ROSE rule in the derivation cohort were 92.5%,
3.8%, 22.4% and 99.2%, and 3.5 and 0.1, respectively. The
ule missed 3 patients (2 of whom were admitted) compared
ith 5 patients with serious outcomes who were discharged
rom the ED (4 of whom would have been identified by the
OSE rule). The area under the receiver-operator charac-
eristic (ROC) curve for the ROSE rule in the derivation
ohort was 0.83 (95% confidence interval [CI]: 0.78 to
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The ROSE Study February 23, 2010:713–21.89). The rule would have potentially prevented 87 admis-
ions in the derivation cohort.
alidation cohort. Between October 27, 2007, and July
2, 2008, there were 951 (1.3%) potentially eligible patients
f 74,840 presentations to the ED. Patients (n  579;
0.9%) were screened, 16 refused to consent, and 13 were
nable to consent and had no relative or caregiver who could
rovide assent. The validation cohort therefore consisted of
50 patients (Fig. 3). Ten patients were lost to follow-up, 1
atient had previously been enrolled in the validation
ohort, and 1 patient later withdrew consent. This left 538
atients for analysis (Table 1), of whom 39 patients had a
rimary outcome (Table 2).
erformance of the ROSE rule. The ROSE rule per-
ormed with a sensitivity, specificity, positive and negative
redictive values, and positive and negative likelihood ratios
f 87.2%, 65.5%, 16.5% and 98.5%, and 2.5 and 0.2,
espectively, when applied to the validation cohort missing
patients, raised troponin I (1.67) and possible MI,
ubarachnoid hemorrhage, basal ganglia hemorrhage on day
9, documented episode of ventricular tachycardia in the
D, and a gastric ulcer found on upper gastrointestinal
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Figure 1 The ROSE Derivation STARD Diagram
A STARD (STAndards for the Reporting of Diagnostic accuracy studies) flow diagram
patients into the derivation cohort of the ROSE (Risk stratification Of Syncope in thndoscopy in a patient who did not undergo an ED rectal ixamination. Two of these patients were discharged by the
mergency clinician (patients with subarachnoid hemor-
hage and basal ganglia hemorrhage), and 1 further patient
as discharged by the emergency clinician but would have
een picked up by the ROSE rule. The area under the ROC
urve for the ROSE rule in the validation cohort was 0.76
95% CI: 0.70 to 0.83). Use of the ROSE rule in the
alidation cohort would have potentially resulted in 80 fewer
dmissions.
orrelation of predictors with serious outcomes. In the
ombined validation and derivation groups, 29 serious
utcomes occurred in patients with a BNP concentration
300 pg/ml. Of these, 23 (79%) were cardiovascular in
rigin and included 7 patients requiring insertion of a
acemaker, 6 with acute MI, 5 with arrhythmia, and 5 with
ulmonary embolus. Positive rectal examination picked up 9
erious outcomes, all of which were gastrointestinal bleeding
r requirement for blood transfusion. Bradycardia picked up
serious outcomes, all of which were in patients who went
n to require pacemaker insertion. Anemia identified 9
erious outcomes: 2 with acute MI, 4 requiring red cell
ransfusion, and 3 other serious outcomes. Chest pain
to 
550) 
0) 
bility Ineligible (n=351) 
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<16 years of age (n=11) 
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February 23, 2010:713–21 The ROSE Studywith acute MI, and 3 who required pacemaker insertion.
inally, Q-wave and saturation 94% on room air were
lightly less specific but picked up mainly cardiovascular and
ulmonary embolus serious outcomes.
Missed” patients and ECG assessment. Table 3 com-
ares patients who were enrolled with those who were
ligible but not enrolled. In the derivation cohort, nonen-
olled patients were younger, although there were no dif-
erences in admission or mortality rates. In the validation
ohort, there were no differences between the 2 groups. The
nterobserver agreement of enrollment eligibility was 0.90
ith a kappa value of 0.69 (95% CI: 0.60 to 0.77).
lectrocardiogram interobserver agreement was between
Selected Characteristics of Analyzed PatientsTable 1 Selected Characteristics of Analyze
Characteristic Derivation
Demographic data
Age, yrs 63.8
Male sex 235 (4
Management
Admitted to hospital 252 (4
Medical history
Previous history of syncope 228 (4
Hypertension 206 (3
Known ischemic heart disease 122 (2
Previous acute myocardial infarction 55 (1
Known valvular heart disease 29 (5
Known history of cardiac failure 27 (5
History of syncope episode
Associated chest pain 39 (7
Prodromal symptoms 326 (6
Associated palpitations 20 (3
Related to exertion 30 (5
Examination findings
Pulse, beats/min 76.1
Systolic BP, mm Hg 130.9
Diastolic BP, mm Hg 68.1
20 mm Hg postural drop 50 (1
% SpO2 on room air 97.2
Heart murmur heard 65 (1
Signs of heart failure 34 (6
FOB present on PR if indicated 16 (1
Associated trauma 167 (3
Syncope cause identified in ED 234 (4
Syncope cause finally identified 348 (6
Arrhythmia in ED 6 (1
ECG findings
Sinus rhythm 451 (9
PR 200 ms 68 (1
Sinus bradycardia 50 beats/min 12 (2
Pathological Q waves 120 (2
Pathological Q waves not III 72 (1
QTc 450 ms 71 (1
QRS 120 ms 27 (5
Values are presented as mean  SD or n (%). Selected characteristic
study analyzed patients in both the derivation (n  529) and validatio
BP  blood pressure; ECG  electrocardiogram; ED  emergency d
QT interval corrected for heart rate..94 and 1.00 for all ECG variables with kappa values oetween 0.85 and 1.00 for all variables except ST-segment
levation (0.66; 95% CI: 0.54 to 0.79) and ST-segment
epression (0.76; 95% CI: 0.67 to 0.85).
NP. In the derivation cohort, BNP was 300 pg/ml in 38
atients (7%), 13 (34%) of whom had a serious outcome or
ll-cause death. Mean age in those with raised BNP was 82 9
ears; 21 patients (55%) had previous hypertension, 15
atients (40%) had previous ischemic heart disease, 12
atients (32%) had previous MI, 12 patients (32%) had
nown cardiac failure, and 11 patients (29%) had signs of
ardiac failure on clinical examination.
In the validation cohort, BNP was 300 pg/ml in 40
atients (7%), 16 patients (40%) of whom had a serious
tients
rt n Validation Cohort n
529 62.4 21.9 538
529 245 (45.5) 538
529 286 (53.2) 538
525 214 (39.9) 537
528 203 (37.9) 536
529 109 (20.4) 535
529 60 (11.2) 535
528 31 (5.8) 536
529 20 (3.7) 535
529 47 (8.7) 538
529 326 (60.7) 537
529 15 (2.8) 538
529 31 (5.8) 537
527 76.2 17.1 537
525 129.7 24.2 534
524 67.4 13.3 534
355 38 (10.6) 358
517 96.8 3.4 523
516 71 (13.4) 531
523 37 (6.9) 534
83 3 (5.3) 57
526 149 (27.9) 534
529 219 (40.7) 538
529 347 (64.9) 535
529 4 (0.7) 538
494 460 (93.7) 491
494 56 (11.4) 491
494 9 (1.8) 491
494 149 (30.4) 490
494 103 (21.0) 490
494 68 (13.9) 490
494 40 (8.1) 491
ROSE (Risk stratification Of Syncope in the Emergency department)
538) cohorts.
ent; FOB  fecal occult blood; PR  per rectum examination; QTc d Pa
Coho
21.2
4.4)
7.6)
3.4)
9.0)
3.1)
0.4)
.5)
.1)
.4)
1.6)
.8)
.7)
18.3
24.0
12.7
4.1)
2.2
2.6)
.5)
9.3)
1.7)
4.2)
5.8)
.1)
1.3)
3.8)
.4)
4.3)
4.6)
4.4)
.5)
s of the
n (n utcome or all-cause death. Mean age in those with raised
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The ROSE Study February 23, 2010:713–21NP was 82  8 years; 23 patients (58%) had previous
ypertension, 19 patients (48%) had previous ischemic heart
isease, 11 patients (28%) had previous MI, 7 patients (18%)
ad known cardiac failure, and 12 patients (30%) had signs of
ardiac failure on clinical examination.
The BNP was an excellent predictor of serious outcome
r all-cause death in the validation cohort. A BNP concen-
ration 300 pg/ml alone predicted 16 (41%) of 39 serious
utcomes or all-cause deaths, including 8 of 22 (36%)
ardiovascular serious outcomes, and 8 of 9 (89%) all-cause
eaths missing a patient who died of complications of a hip
rthroplasty (99.8% negative predictive value for all-cause
eath). The area under the ROC curve of BNP with serious
utcome or all-cause death was 0.81 (95% CI: 0.74 to 0.88).
he areas under the ROC curves of BNP with cardiovas-
ular serious outcome or all cause-death were 0.79 (95% CI:
.69 to 0.88) and 0.93 (95% CI: 0.85 to 1.00), respectively.
iscussion
e have derived and validated a CDR that is safe and
imple to use. The ROSE rule consists of 7 variables easily
emembered by the pneumonic “BRACES” (Fig. 2). It
otentially avoids 149 unnecessary admissions at the ex-
ense of missing 4 more patients with a serious outcome and
o deaths for every 1,000 patients presenting with syncope.
f incorporated into clinical practice it could potentially save
36,000 admissions and $734 million in hospital stay costs
nnually in the U.S. (22). A resource-use impact analysis
tudy would be necessary to confirm this.
Syncope is an important problem that cardiologists see on
daily basis in their clinical practices. It is well-established
hat cardiac causes of syncope are the most serious and are
ssociated with the worst outcome (23). However, at
resent, it is often unclear whether a patient with syncope
eeds to be admitted and whether their syncope is likely to
e due to a cardiac cause best managed under the care of a
ardiologist.
This is the first study to use point-of-care BNP as a novel
ummary of Outcome MeasuresTable 2 Summary of Outcome Measures
Derivation Cohort
(n  529)
Validation Cohort
(n  538)
Primary outcome 40 39
SO 39 35
ACD 7 9
Both SO and ACD 6 5
Obvious diagnosis in ED 17 16
Secondary outcomes
Cardiovascular SO 20 22
Syncope-related death 3 8
ummary of the main outcomemeasures in both the derivation and validation cohorts of the ROSE
Risk stratification Of Syncope in the Emergency department) study. The main primary end point
as the combination of serious outcome (SO) and all-cause death (ACD) at 1 month after
mergency department (ED) presentation. Secondary end points were syncope-related death and
ardiovascular death.redictor of outcome in patients presenting with syncope.ncreasingly, BNP is being recognized as a marker of future
isk and death in a range of cardiovascular disease states (13)
nd not just heart failure (24). Here we have extended these
bservations to a broad group of patients presenting with
yncope and have demonstrated that it is the single most
owerful predictor of adverse outcome, particularly death.
lthough in the United Kingdom only 5% of EDs currently
ave point-of-care BNP testing (25), 44% have point-of-
are testing facilities (25) and almost all have rapid access to
aboratory BNP, because of National Institute of Health
nd Clinical Excellence recommendations (26).
One possible limitation to the utility of BNP for syncope
isk stratification is that it might be identifying patients who
re older and who have other evidence of structural heart
isease. By contrast, BNP might be a more objective and
ore specific marker of heart disease than a subjective
linical history or examination.
Many EDs use protocols (25) based on international
yncope guidelines (15,16,27–29) in an attempt to ensure all
igh-risk patients are admitted. Such guidelines can be
mpractical, cumbersome, and nonspecific, leading to need-
ess admissions. The ideal CDR would be simple and repro-
ucible, admit all patients with serious underlying pathologies,
nd discharge all low-risk patients. We believe the ROSE rule
s currently the closest rule to achieve these aims.
Although caution must be used when interpreting com-
arison with other CDRs, the performance of the ROSE
ule in the validation cohort was compared with the perfor-
ance of existing syncope CDRs (1,3,5,6) and the short-
erm risk factors from the recently published STePS (Short-
erm Prognosis of Syncope) study (7). These CDRs were
nable to avoid admissions without a large unacceptable
ncrease in missed serious outcomes. The only 2 rules that
id not miss serious outcomes required admission of many
ore patients and include admission criteria such as “age over
5” (1). Our study and other recent studies (3,5–7) also suggest
The ROSE rule 
Admit if any of the following are present: 
B B NP level ≥ 300pg/ml 
B radycardia ≤50 in Emergency Department or pre-hospital 
R R ectal examination showing fecal occult blood (if suspicion of 
gastrointestinal bleed) 
A A nemia - Hemoglobin ≤90 g/l 
C C hest pain associated with syncope 
E E CG showing Q wave (not in lead III)  
S S aturation ≤94% on room air 
Figure 2 The ROSE Rule With
“BRACES” Mnemonic Aide Memoire
A patient should be considered high-risk and admitted if any of the 7 criteria in
the ROSE (Risk stratification Of Syncope in the Emergency department) rule are
present. BNP  B-type natriuretic peptide; ECG  electrocardiogram.
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February 23, 2010:713–21 The ROSE Studyhat risk of serious outcome is less than previously reported
14,23), and most patients do not require admission.
Our rule includes a rectal examination. We are not
dvocating performing such an examination on all patients
resenting with syncope. During both the derivation and
alidation studies, rectal examination was performed in 13%
f patients at the discretion of the treating physician if there
as any suspicion of gastrointestinal bleeding. We suggest
hat this approach is used for the ROSE rule.
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Analysis 
Follow-Up 
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Eligible 
Assessed fo
(n=13
Numbers part
baseline data coll
Analyzed 
Excluded from 
Screened 
Figure 3 The ROSE Validation STARD Diagram
A STARD flow diagram showing recruitment of patients into the validation cohort o
omparison of Enrolled and Nonenrolled PatientsTable 3 Comparison of Enrolled and Nonenrolled Patients
Derivation Cohort
Enrolled
(n  550)
Not Enrolled
(n  340)
Mean age, yrs 63.9 21.6 58.2 24.3
Male sex 247 (44.9) 141 (41.5)
Admitted 254 (46.2) 178 (52.4)
Discharged 296 (53.8) 162 (47.6)
Death 7 (1.3) 10 (2.9)
alues are presented as mean  SD or n (%). Comparison between enrolled patients and nonenro
he Emergency department) study. Characteristics assessed are mean age, sex, decision to admit or d
resentation. *Student t test (2-tailed); †chi-square with Yates’ continuity correction.tudy limitations. As yet it has only been derived and validated
n a single United Kingdom center. Recruitment into an external
alidation study is currently ongoing. Secondly, although saving
49 unnecessary admissions/1,000 patients with no extra deaths,
he ROSE rule misses 4 more patients with serious outcome.
lthough defined as serious due to our rigorous definition, many
vents were not life-threatening, and the clinical benefit of a large
umber of prevented admissions potentially outweighs the small
umber of missed serious outcomes.
to 
550) 
1) 
bility 
Ineligible (n=423) 
Previously enrolled (n=8) 
Likely seizure (n=136) 
Unclear history (n=105) 
Alcohol related (n=156) 
<16 years of age (n=18) 
Not enrolled by treating 
doctor (n=372) 
Previously enrolled to 
validation cohort (n=1) 
ing at 
 (n=549) 
38) 
sis (n=0) 
Lost to follow-up (n=10) 
(None of these patients 
represented to any local 
hospital or died in the 
community) 
9) 
Refused to participate 
(n=16) 
Unable to consent 
(n=13) 
Consent withdrawn (n=1) 
OSE study. Abbreviations as in Figure 1.
Validation Cohort
lue
Enrolled
(n  550)
Not Enrolled
(n  401) p Value
2* 62.1 22.0 59.2 24.2 0.051*
† 250 (45.5) 169 (42.1) 0.34†
† 287 (52.2) 224 (55.9) 0.29†
† 263 (47.8) 177 (44.1) 0.29†
† 10 (1.8) 7 (1.7) 1.00†
tients in both the derivation and validation cohorts of the ROSE (Risk stratification Of Syncope inted in
y (n=
(n=95
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74) 
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ection
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The ROSE Study February 23, 2010:713–21Although the ROSE rule is able to detect high-risk
atients, it is not clear whether the identification of risk and
onsequent admission affects outcome. This would require a
arge multicenter randomized controlled trial, with a cluster
esign to avoid contamination, to implement the ROSE
ule to determine whether this strategy was effective and
afe.
The ROSE predictive criteria including BNP might be
arkers of poor outcome irrespective of whether it is
pplied to patients presenting with syncope. This issue
ould be addressed by comparing outcomes with a control
onsyncopal comparator group. However, the selection,
atching, and recruitment of such a comparator group
ould be challenging, and its absence does not detract from
he important clinical question of how to manage patients
ith an emergency presentation of syncope.
Our CDR was derived with patients presenting with
ndifferentiated syncope. This was because during our pilot
tudy (21) it became apparent that the definition of an
obvious” diagnosis differs widely between individual clini-
ians, and in this study, only 42% (33 of 79) of subsequent
erious outcomes and deaths were apparent at initial ED
ssessment. A CDR should only be used in conjunction
ith physician judgment and after a full history and exam-
nation and bedside investigations have been performed.
learly a CDR is not required when serious pathology is
pparent; subarachnoid hemorrhage is an example. We
uggest that the ROSE rule should be applied in the acute
etting to patients in whom a clear diagnosis is not apparent
fter initial assessment. The ROSE rule identified 85% (39
f 46) of patients whose subsequent serious outcome or
eath was not apparent in the ED.
onclusions
e have derived and validated a rule that has excellent
ensitivity and negative predictive value that allows for the
dentification of high-risk patients with an emergency
resentation of syncope. The ROSE rule potentially reduces
dmission rates by 30% and might perform better than
xisting CDRs. The BNP seems to be particularly useful in
he identification of serious cardiovascular outcomes and
ll-cause death in such patients. The use of the ROSE CDR
nd BNP estimation holds major promise and requires
urther external validation and investigation in this impor-
ant group of patients.
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APPENDIX
or a table comparing ROSE rule performance with existing clinical
ecision rules in the validation cohort, please see the online version of this
rticle.
